{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:07:07Z","timestamp":1791094027629,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1097\/coc.0b013e3181131db9","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T08:06:45Z","timestamp":1236240405000},"page":"84-88","source":"Crossref","is-referenced-by-count":26,"title":["Phase II Study of Imatinib in Unresectable Hepatocellular Carcinoma"],"prefix":"10.1097","volume":"31","author":[{"given":"Albert Y.","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Levitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210128","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002.","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"R2-14-20210128","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00000658-199304000-00009","article-title":"Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years.","volume":"217","author":"Nagasue","year":"1993","journal-title":"Ann Surg"},{"key":"R3-14-20210128","first-page":"1219","article-title":"Recurrence of hepatocellular carcinoma after surgery.","volume":"83","author":"Yamamoto","year":"1996","journal-title":"Br J Surg"},{"key":"R4-14-20210128","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0168-8278(97)80160-2","article-title":"Cytokines and the liver.","volume":"27","author":"Simpson","year":"1997","journal-title":"J Hepatol"},{"key":"R5-14-20210128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.20767","article-title":"Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis.","volume":"42","author":"Lau","year":"2005","journal-title":"Hepatology"},{"key":"R6-14-20210128","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1038\/sj.onc.1209083","article-title":"A crucial function of PDGF in TGF-beta-mediated cancer hepatocytes.","volume":"25","author":"Gotzmann","year":"2006","journal-title":"Oncogene"},{"key":"R7-14-20210128","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"R8-14-20210128","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"R9-14-20210128","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumors.","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"key":"R10-14-20210128","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cyto.2005.06.005","article-title":"Expression patterns of PDGF-A, -B, -C and -D and the PDGF-receptors alpha and beta in activated rat hepatic stellate cells (HSC).","volume":"31","author":"Breitkopf","year":"2005","journal-title":"Cytokine"},{"key":"R11-14-20210128","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1158\/1078-0432.CCR-05-0944","article-title":"Over expression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential.","volume":"11","author":"Zhang","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R14-14-20210128","first-page":"2671","article-title":"HER-2\/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma.","volume":"23","author":"Potti","year":"2003","journal-title":"Anticancer Res"},{"key":"R15-14-20210128","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.canlet.2004.06.045","article-title":"Expression of c-kit protooncogene in human hepatocellular carcinoma.","volume":"217","author":"Chung","year":"2005","journal-title":"Cancer Lett"},{"key":"R16-14-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1309\/LETTWN3LUF516HR0","article-title":"Occurrence of c-kit+ tumor cells in hepatitis B virus-associated hepatocellular carcinoma.","volume":"124","author":"Lee","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"R17-14-20210128","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00001813-200404000-00014","article-title":"Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis.","volume":"15","author":"Ramadori","year":"2004","journal-title":"Anticancer Drugs"},{"key":"R18-14-20210128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000089990","article-title":"Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.","volume":"69","author":"Eckel","year":"2005","journal-title":"Oncology"},{"key":"R19-14-20210128","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"R20-14-20210128","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma.","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"R21-14-20210128","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1200\/JCO.2005.14.696","article-title":"Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.","volume":"23","author":"Philip","year":"2005","journal-title":"J Clin Oncol"},{"key":"R22-14-20210128","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1002\/hep.21063","article-title":"Functional genomics of hepatocellular carcinoma.","volume":"43","author":"Thorgeirsson","year":"2006","journal-title":"Hepatology"},{"key":"R23-14-20210128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009053765771","article-title":"Molecularly targeted therapy for gastrointestinal cancer.","volume":"5","author":"Wiedmann","year":"2005","journal-title":"Curr Cancer Drug Targets"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000421-200802000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:52:55Z","timestamp":1786038775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-200802000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3181131db9","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}